Req. No. 307 Page 1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
STATE OF OKLAHOMA
1st Session of the 59th Legislature (2023)
SENATE BILL 668 By: Standridge
AS INTRODUCED
An Act relating to the Uniform Controlled Dangerous
Substances Act; amending 63 O.S. 2021, Section 2-322,
which relates to precursor substances requiring
permit or license; removing certain drugs from
requiring certain permitting or licensing ; amending
63 O.S. 2021, Section 2 -210, which relates to
Schedule IV; including certain drug ; and providing an
effective date.
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -322, is
amended to read as follows:
Section 2-322. A. No person or business shall pos sess, sell,
manufacture, transfer, or otherwise fur nish any of the following
precursor substances without first having a permit or license issued
by the Director of the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control, except as provided in S ection 2-327 of this
title:
1. D-Lysergic acid;
2. Ergotamine and its salts;
3. Ergonovine and its salts;
Req. No. 307 Page 2 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
4. Methylamine;
5. Ethylamine;
6. Phenyl-2-Propanone;
7. Phenylacetic acid and its salts;
8. Ephedrine, its salts, optical isomers and salts o f optical
isomers;
9. Norpseudoephedrine, its salt s, optical isomers, and salts of
optical isomers;
10. Phenylpropanolamine, its salts, optical isomers and salts
of optical isomers;
11. 9. Benzyl cyanide;
12. 10. N-methylephedrine, its salts, optical i somers and salts
of optical isomers;
13. Pseudoephedrine, its salts, optical isomers and salts of
optical isomers;
14. 11. Chloroephedrine, its salts, optical iso mers and salts
of optical isomers;
15. 12. Piperidine and its salts;
16. 13. Pyrrolidine and its salts;
17. 14. Propionic anhydride;
18. 15. Isosafrole;
19. 16. Safrole;
20. 17. Piperonal; and
21. 18. Red Phosphorus.
Req. No. 307 Page 3 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
B. Upon completion of an applica tion for a license pursuant to
Section 2-323 of this title, or a permit pursuant to Section 2-324
of this title, the Director of the Oklahoma State Bureau of
Narcotics and Dangerous Drugs Control shall either grant or deny
such license or permit. A denial of an application for a permit or
license shall be handled as provided by Section 2 -325 of this title.
SECTION 2. AMENDATORY 63 O.S. 2021, Section 2 -210, is
amended to read as follows:
Section 2-210. A. Any material, compound, mixture, or
preparation which contains any quantity of the following substances
having a potential for abuse associated wit h a stimulant or
depressant effect on the central nervous system:
1. Chloral betaine;
2. Chloral hydrate;
3. Ethchlorvynol;
4. Ethinamate;
5. Meprobamate;
6. Paraldehyde;
7. Petrichloral;
8. Diethylpropion;
9. Phentermine;
10. Pemoline;
11. Chlordiazepoxide;
Req. No. 307 Page 4 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
12. Chlordiazepoxide and its salts, but not including
chlordiazepoxide hydrochloride and clidinium bromide or
chlordiazepoxide and water -soluble esterified estrogens;
13. Diazepam;
14. Oxazepam;
15. Clorazepate;
16. Flurazepam and its sa lts;
17. Clonazepam;
18. Barbital;
19. Mebutamate;
20. Methohexital;
21. Methylphenobarbital;
22. Phenobarbital;
23. Fenfluramine;
24. Pentazocine;
25. Propoxyphene;
26. Butorphanol;
27. Alprazolam;
28. Halazepam;
29. Lorazepam;
30. Prazepam;
31. Temazepam;
32. Triazolam;
33. Carisoprodol;
Req. No. 307 Page 5 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
34. Dichloralphenazone;
35. Estazolam;
36. Eszopiclone;
37. Midazolam;
38. Modafinil;
39. Zaleplon;
40. Zolpidem;
41. Tramadol;
42. Bromazepam;
43. Suvorexant;
44. Phenazepam;
45. Etizolam; or
46. Clonazolam; or
47. Xylazine.
B. 1. The following nonnarcotic substances, which may, unde r
the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301),
be lawfully sold over the counter without a prescription, are
excluded from all schedules of c ontrolled substances under this
title:
a. Breathe-Aid,
b. BronCare,
c. Bronchial Congestion,
d. Bronkaid Tablets,
e. Bronkaid Dual Action Caplets,
Req. No. 307 Page 6 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
f. Bronkotabs,
g. Bronkolixir,
h. NeoRespin,
i. Pazo Hemorrhoid Ointment and Suppositories,
j. Primatene Tablets,
k. Primatene “Dual Action” Formula,
l. Quelidrine,
m. Resp, and
n. Vatronal Nose Drops.
2. At the request of any person, the Director may exempt any
other drug product containing ephedrine from being included as a
Schedule IV controlled substance if such product:
a. is labeled and marketed in a manner consistent with
the pertinent OTC tentat ive final or final monograph
issued by the FDA, and
b. is manufactured and distributed for legitimate
medicinal use and in a ma nner that reduces or
eliminates the likelihood of abuse.
3. In making a determination regarding a drug product, the
Director, after notice and hearing, shall consider the following:
a. the history and current pattern of abuse,
b. the name and labeling of the product,
c. the intended manner of distribution, advertising and
promotion of the product, and
Req. No. 307 Page 7 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. other factors as may be rel evant to and consistent
with the public health and safety.
4. The hearing shall be held in accordance with the
Administrative Procedures Act.
5. A list of curren t drug products meeting exemption
requirements under this subsection may be obtained from the Bureau
upon written request.
C. The Board of Pharmacy may except by rule any compound,
mixture, or preparation containing any depressant substance listed
in subsection A of this section from the application of all or any
part of the Uniform Controlled Da ngerous Substances Act, Section 2 -
101 et seq. of this title, if the compound, mixture, or preparation
contains one or more acti ve medicinal ingredients not having a
depressant effect on the central nervous system, and if the
admixtures are included therein in combinations, quantity,
proportion, or concentration that vitiate the potential for abuse of
the substances which have a de pressant effect on the central nervo us
system.
SECTION 3. This act shall become effective November 1, 2023.
59-1-307 JES 1/18/2023 11:32:24 AM